# Yozma Group

> Yozma Group is a VC fund in Tel Aviv backing Software and Health Care. See 28 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tel Aviv, Israel
- Total investments: 28
- Last investment: Nov 2024
- Lead investor: 36%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/theyozmagroup/
- X (Twitter): https://twitter.com/theyozmagroup?lang=en
- Website: http://www.yozma.com/home/

Yozma Group is a VC fund in Tel Aviv focused on Software and Health Care. Yozma has earned worldwide recognition as the creator of the Israeli venture capital industry. Yozma makes equity investments in technology companies engaged in fields where Israel has demonstrated world leadership. The Group targets high-growth companies in the sectors of Communications, Information Technologies, and Life Sciences. Yozmaeffectively created the Israeli venture capital market in 1993 through the formation of its first venture fund, Yozma I. Originating from a government program aimed at prompting venture investments in Israel, Yozma I has transformed the domestic landscape of private equity investments. Over a period of three years, the Group established ten drop-down funds, each capitalized with more than $20 million. In parallel Yozma started making direct investments in start-up companies. This marked the beginning of a professionally managed venture capital market in Israel. Today, Yozma's drop-down funds constitute the backbone of the Israeli venture market.

## Contacts

5 contacts available for Yozma Group. Shizune tracks 10 team members at Yozma Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/yozma-group?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $400k–$4.5M |
| Series B | $2.5M–$59M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 5 | 18% |
| Health Care | 5 | 18% |
| Medical | 4 | 14% |
| Biotechnology | 3 | 11% |
| Medical Device | 3 | 11% |

41 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 25% |
| Funding Round | 6 | 21% |
| Seed | 4 | 14% |
| Series A | 3 | 11% |
| Series C | 2 | 7% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 10 | 36% |
| United States | 4 | 14% |
| South Korea | 3 | 11% |
| India | 1 | 4% |
| Australia | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Allen Song | Director | 0 | https://shizune.co/investors/profile/allen-song-090c |
| Chris Hwang | Managing Partner | 0 | https://shizune.co/investors/profile/chris-hwang-8d18 |
| Dongjun Lee | CEO, Domestic Business | 0 | https://shizune.co/investors/profile/dongjun-lee-8bef |
| Eunha Jeong | Associate (AC Div.) | 0 | https://shizune.co/investors/profile/eunha-jeong |
| Eunji Jang | Associate (Operation Div.) | 0 | https://shizune.co/investors/profile/eunji-jang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| RoomGenie | An AI-powered chatbot for hotels revolutionizes the way guests interact with in-room services by enabling seamless cross-selling and upselling. Integrated within smart devices or hotel apps, this AI solution leverages natural language processing (NLP) to communicate with guests in a conversational and personalized manner.From booking spatreatments and restaurant reservations to upgrading rooms or scheduling late checkouts, the chatbot intuitively identifies guest preferences and suggests relevant services. It analyzes data such as guest profiles, previous stays, and real-time behavior to deliver tailored recommendations, boosting both guest satisfaction and revenue.Available 24/7, the chatbot ensures instant responses to guest inquiries, reducing dependence on front-desk staff and enhancing operational efficiency. Additionally, it supports multiple languages, catering to a global clientele and making communication barrier-free. Hotels can integrate the AI chatbot with their property management systems (PMS) and point-of-sale (POS) platforms to streamline service delivery and track guest interactions.The solution empowers hotels to provide a hyper-personalized, tech-forward experience, which appeals to modern travelers. By automating cross-selling and upselling opportunities while improving guest engagement, the chatbot not only enhances the overall stay experience but also drives incremental revenue, making it a vital tool for the hospitality industry. | $400K | Seed | Nov 10, 2024 |  |
| Meat.The End | Imagine plant-based meat alternatives that offer the texture, flavour, and appearance of animal proteins. Using innovations in extrusion processing, we develop new protein texturizing technologies that create plant-based products that mimic the texture of animal proteins. The texture of plant-based protein products still poses a barrier toconvincing consumers to adopt alternatives to meat. But current approaches to creating plant-based meat substitutes are falling short in building a protein structure that mirrors a meaty texture experience. We help plant-based protein producers satisfy consumers’ desire for meaty texture and appearance. By improving texture, our techniques enhance the eating experience of plant-based products. The result: a more convincing and satisfying alternative to replace animal-based foods. | $3.1M | Seed | Dec 01, 2022 |  |
| Meat.The End | Imagine plant-based meat alternatives that offer the texture, flavour, and appearance of animal proteins. Using innovations in extrusion processing, we develop new protein texturizing technologies that create plant-based products that mimic the texture of animal proteins. The texture of plant-based protein products still poses a barrier toconvincing consumers to adopt alternatives to meat. But current approaches to creating plant-based meat substitutes are falling short in building a protein structure that mirrors a meaty texture experience. We help plant-based protein producers satisfy consumers’ desire for meaty texture and appearance. By improving texture, our techniques enhance the eating experience of plant-based products. The result: a more convincing and satisfying alternative to replace animal-based foods. | $4M | Seed | Apr 01, 2022 |  |
| Fine Data Lab | Fine Data Lab is a digital data analysis company offering digital marketing consulting, analytics, and data analytics solutions. |  | Seed | Nov 27, 2021 |  |
| Illumigyn | Illumigyn incorporates existing machine vision technologies into a compact imaging colposcope for medical applications in an effort to eliminate the inherent subjectivity of cervical exams. Its Gynescope is a patented imaging colposcope that delivers 15-micron image resolution over a wide field of view and a range of working distances. TheGynescope also has multispectral illumination options, allowing early detection of cervical cancer while meaningfully reducing misdiagnoses. The Gynescope enables sophisticated imaging with simultaneous complex interventional procedures to support the best clinical outcomes. | $33M | Venture - Series Unknown | Nov 03, 2021 |  |
| OP.GG | OP.GG creates profiles for gamers by analyzing game data from the games they play. Through these profiles, gamers can improve their gameplay and see the game performance of their opponents and friends. Currently OP.GG has services for League of Legends, Overwatch and PUBG with over 28 million monthly users from around the world. | $20M | Series B | Jun 01, 2021 |  |
| UltraSight | UltraSight aims to revolutionize ultrasound through the power of machine learning to enable more accurate and timely clinical decisions. The UltraSight automated guidance system helps bring the benefits of cardiac imaging to healthcare professionals in new care settings, allowing patients access to ultrasound anywhere. UltraSight won the TCT 2020Innovation Competition which took place during the Transcatheter Cardiovascular Therapeutics world conference. For mor information please visit us at www.ultrasight.com | $13M | Series B | May 11, 2021 |  |
| Todos Medical | The Todos Medical team is a multidisciplinary group that includes experts in medicine, physics, biochemistry, digital signal processing, and electrical engineering. This unique combination of the sciences gives TBIA its competitive advantage and uniqueness. | $3.4M | Convertible Note | Jan 25, 2021 |  |
| Todos Medical | The Todos Medical team is a multidisciplinary group that includes experts in medicine, physics, biochemistry, digital signal processing, and electrical engineering. This unique combination of the sciences gives TBIA its competitive advantage and uniqueness. | $3.4M | Post-IPO Debt | Jan 25, 2021 |  |
| Nanox Imaging | Nanox offers the Nanox System as a preventative healthcare Medical Screening As A Service (MSaaS). Nanox field-effect cathode technology was originally developed for use in high-definition flat panel displays. Over time, the manufacturing processes were ported from glass to silicon, enabling enormous increases in power density and uniformity.After more than 20 years of research and development, with over $1B invested, their team of engineers has developed unique intellectual property, patents, and capability to design and build high-powered field-effect cathodes that outperform all previous efforts. Nanox’s proprietary cold cathode technology greatly expands the capabilities of X-ray imaging. At the core of their high-powered cold cathode is a “chip” of nano-scale structures created using proprietary nanofabrication techniques. The chip is designed to support various use cases of medical imaging and will be supported by peripheral technologies in order to translate their benefits into various real-world applications. | $59M | Series B | Jul 28, 2020 |  |

10 of 28 investments shown.

## Co-investors
- [Giza Venture Capital](https://shizune.co/investors/profile/giza-venture-capital) — VC Fund, 3 deals together
- [Ofer Hi-Tech](https://shizune.co/investors/profile/ofer-hi-tech) — VC Fund, 3 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together
- [Ascend Technology Ventures](https://shizune.co/investors/profile/ascend-technology-ventures) — VC Fund, 2 deals together
- [Big Idea Ventures](https://shizune.co/investors/profile/big-idea-ventures) — VC Fund, 2 deals together
- [Redwood Venture Partners](https://shizune.co/investors/profile/redwood-venture-partners) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Israel](https://shizune.co/investors/health-care-vc-funds-israel)
- [Medical VC Funds in Middle East](https://shizune.co/investors/medical-vc-funds-middle-east)
- [Medical Investors in Israel](https://shizune.co/investors/medical-investors-israel)
- [Medical VC Funds in Israel](https://shizune.co/investors/medical-vc-funds-israel)
- [Biotech Investors in Israel](https://shizune.co/investors/biotech-investors-israel)
- [Biotech VC Funds in Israel](https://shizune.co/investors/biotech-vc-funds-israel)

## FAQ

### What does Yozma Group invest in?

Yozma Group invests primarily in Software, Health Care and Medical startups, most often at Series B and Funding Round stage. Most of the 28 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Yozma Group's check size?

Yozma Group typically joins rounds of $400k–$4.5M at Seed and $2.5M–$59M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Yozma Group participates in.

### How do I contact Yozma Group?

Public channels for Yozma Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Yozma Group?

The team at Yozma Group includes Allen Song (Director), Chris Hwang (Managing Partner) and Dongjun Lee (CEO, Domestic Business), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co